mRNA vaccine

Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine byCTLA-4 siRNA-Mediated Immune Checkpoint Modulation inTriple Negative Breast Cancer Mice Model

| Published Research Articles

🔬 Introduction Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer. Unlike other forms, TNBC lacks estrogen, progesterone, and HER2 receptors, limiting targeted therapy options and increasing reliance on chemotherapy.Recent advances in RNA-based cancer vaccines and immunotherapy have opened new therapeutic pathways. However, most mRNA vaccines focus only […]

Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine byCTLA-4 siRNA-Mediated Immune Checkpoint Modulation inTriple Negative Breast Cancer Mice Model Read Post »

SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®,induces robust humoral and cellular immunity in mice andnon-human primates

| Published Research Articles

🔬 Introduction In the race to develop effective vaccines against COVID-19, Iranian researchers have designed an innovative mRNA-based vaccine candidate known as COReNAPCIN®. Using a lipid nanoparticle (LNP) delivery system, this vaccine aims to safely express the full-length SARS-CoV-2 spike (S) protein in host cells — triggering strong immune responses. Recent preclinical results show high

SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®,induces robust humoral and cellular immunity in mice andnon-human primates Read Post »

Liposome/AZIF-8 Janus nanoplatforms: Promising nanocarriers forimproving chemotherapeutic outcomes in breast cancer treatment

| Published Research Articles

🔬 Introduction Researchers at Mashhad University of Medical Sciences have developed an innovative dual-delivery nanoplatform designed to enhance the effectiveness of chemotherapy in breast cancer. This novel Janus nanoparticle, combining AZIF-8 and liposomes, offers targeted, simultaneous delivery of both hydrophilic and hydrophobic drugs. 🧪What Makes This Nanoparticle Special? 🧫 Key Findings (In Vitro & In

Liposome/AZIF-8 Janus nanoplatforms: Promising nanocarriers forimproving chemotherapeutic outcomes in breast cancer treatment Read Post »

nanosynthes logo

Contact us

info@nanosynthes.com
Sales: Loshani@nanosynthes.com
Linkedin

33 Manor Place, Bryndwr, Christchurch, 8053,
New Zealand

Newsletter Subscription

©2025. NanoSynthes All Rights Reserved.

Scroll to Top